Table 1.

Antibody-containing novel combination regimens for RRMM.

Regimen	Phase	N	≧PR (%)	≧VGPR (%)	≧CR (%)	Median PFS (mo.)	References (Number)
Elotuzumab+Ld vs Ld	III	321 vs 325	78.5 vs 65.5	31 vs 29	4 vs 7	19.4 vs 14.9	Lonial S et al., 2015 (8)
Elotudumab+Bd vs Bd	II	77 vs 75	65 vs 63	37 vs 27	4 vs 4	9.7 vs 6.9	Jakubowiak A et al., 2016 (24)
Elotudumab+Td	II	40	38	18	8	3.9	Mateos MV et al., 2016 (25)
Daratumumab+Bd vs Bd	III	251 vs 247	82.9 vs 63.2	59.2 vs 29.1	19.2 vs 9.0	60.7% vs 26.9% (at 12-mo)	Palumbo A et al., 2016 (9)
Daratumumab+Ld vs Ld	III	286 vs 283	92.9 vs 76.4	75.8 vs 44.2	43.1 vs 19.2	83.2% vs 60.1% (at 12-mo)	Dimopoulos MA et al., 2016 (10)
Daratumumab+Pd	Ib	103	60	42	17	8.8 (at a median follow-up of 13.1 mo.)	Chari A et al., 2017 (11)
Pembrolizumab+Pd	II	48	60	27	8	17.4 (at a median follow-up of 15.8 mo.)	Badros A et al., 2017 (12)

Rd, lenalidomide and dexamethazone; Bd, bortezomib and dexamethasone; Td, thalidomide and dexamethasone; Pd, pomalidomide and dexamethasone.